KR20230058467A - 안지오텐신 ii와 관련된 질환의 치료에 사용하기 위한 신규한 화합물 - Google Patents
안지오텐신 ii와 관련된 질환의 치료에 사용하기 위한 신규한 화합물 Download PDFInfo
- Publication number
- KR20230058467A KR20230058467A KR1020237010733A KR20237010733A KR20230058467A KR 20230058467 A KR20230058467 A KR 20230058467A KR 1020237010733 A KR1020237010733 A KR 1020237010733A KR 20237010733 A KR20237010733 A KR 20237010733A KR 20230058467 A KR20230058467 A KR 20230058467A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- compound
- imidazol
- phenyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2013721.2 | 2020-09-01 | ||
| GBGB2013721.2A GB202013721D0 (en) | 2020-09-01 | 2020-09-01 | New compounds |
| PCT/GB2021/052254 WO2022049372A1 (en) | 2020-09-01 | 2021-09-01 | Novel compounds for use in the treatment of diseases associated with angiotensin ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230058467A true KR20230058467A (ko) | 2023-05-03 |
Family
ID=72749608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237010733A Withdrawn KR20230058467A (ko) | 2020-09-01 | 2021-09-01 | 안지오텐신 ii와 관련된 질환의 치료에 사용하기 위한 신규한 화합물 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230348444A1 (https=) |
| EP (1) | EP4208460A1 (https=) |
| JP (1) | JP2023539614A (https=) |
| KR (1) | KR20230058467A (https=) |
| CN (1) | CN116568682A (https=) |
| AU (1) | AU2021337193A1 (https=) |
| CA (1) | CA3189240A1 (https=) |
| CL (1) | CL2023000580A1 (https=) |
| CO (1) | CO2023002347A2 (https=) |
| GB (1) | GB202013721D0 (https=) |
| IL (1) | IL300582A (https=) |
| MX (1) | MX2023002522A (https=) |
| WO (1) | WO2022049372A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4313953A1 (en) * | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB202104038D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| WO2024149712A1 (en) * | 2023-01-09 | 2024-07-18 | Vicore Pharma Ab | Selective angiotensin ii compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| KR100938817B1 (ko) * | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2006235698B2 (en) * | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| GB201913603D0 (en) * | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
-
2020
- 2020-09-01 GB GBGB2013721.2A patent/GB202013721D0/en not_active Ceased
-
2021
- 2021-09-01 EP EP21773137.1A patent/EP4208460A1/en active Pending
- 2021-09-01 WO PCT/GB2021/052254 patent/WO2022049372A1/en not_active Ceased
- 2021-09-01 KR KR1020237010733A patent/KR20230058467A/ko not_active Withdrawn
- 2021-09-01 AU AU2021337193A patent/AU2021337193A1/en not_active Abandoned
- 2021-09-01 JP JP2023513654A patent/JP2023539614A/ja active Pending
- 2021-09-01 CA CA3189240A patent/CA3189240A1/en active Pending
- 2021-09-01 US US18/023,164 patent/US20230348444A1/en active Pending
- 2021-09-01 IL IL300582A patent/IL300582A/en unknown
- 2021-09-01 CN CN202180053934.XA patent/CN116568682A/zh active Pending
- 2021-09-01 MX MX2023002522A patent/MX2023002522A/es unknown
-
2023
- 2023-02-28 CL CL2023000580A patent/CL2023000580A1/es unknown
- 2023-02-28 CO CONC2023/0002347A patent/CO2023002347A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023002347A2 (es) | 2023-05-19 |
| CN116568682A (zh) | 2023-08-08 |
| CA3189240A1 (en) | 2022-03-10 |
| MX2023002522A (es) | 2023-03-13 |
| IL300582A (en) | 2023-04-01 |
| JP2023539614A (ja) | 2023-09-15 |
| AU2021337193A1 (en) | 2023-03-23 |
| EP4208460A1 (en) | 2023-07-12 |
| WO2022049372A1 (en) | 2022-03-10 |
| CL2023000580A1 (es) | 2023-10-06 |
| GB202013721D0 (en) | 2020-10-14 |
| US20230348444A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230058467A (ko) | 안지오텐신 ii와 관련된 질환의 치료에 사용하기 위한 신규한 화합물 | |
| KR20230004501A (ko) | 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물 | |
| JP7773988B2 (ja) | アンジオテンシンｉｉに関連する疾患の治療における使用のためのイミダゾリルチオフェンスルホニルカルバメート | |
| US12441718B2 (en) | Selective angiotensin II compounds | |
| WO2022200786A1 (en) | Selective angiotensin ii receptor ligands | |
| GB2605148A (en) | New compounds | |
| JP2026502510A (ja) | 選択的アンジオテンシンｉｉ化合物 | |
| JP2024511453A (ja) | 選択的アンジオテンシンｉｉ受容体リガンド | |
| WO2022200787A1 (en) | Selective angiotensin ii receptor ligands | |
| CN117222624A (zh) | 选择性血管紧张素ii受体配体 | |
| HK40081690B (en) | Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii | |
| HK40081690A (en) | Imidazolyl thiophene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |